Sponsor of the Day:
Jerkmate
https://www.nature.com/articles/s43018-025-01044-8?error=cookies_not_supported&code=2fbb6d42-1f8b-4dae-b371-8ff08ff90115
Radiopharma pipeline builds ahead of key data | Nature Cancer
Oct 6, 2025 - Investment continues as the field awaits phase 3 readouts for next-generation radioligand therapies in 2026.
builds aheadkey dataradiopharmapipelinenature
https://drug-dev.com/radioligand-therapies-affibody-molecules-a-versatile-approach-to-radiopharma/
RADIOLIGAND THERAPIES - Affibody Molecules: A Versatile Approach to Radiopharma
Apr 15, 2026 - Fredrik Frejd reviews Affibody’s lead RLT candidate, ABY-271, currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast...
therapiesmoleculesversatileapproachradiopharma
https://www.itm-radiopharma.com/home
ITM Radiopharma: Lead radiopharmaceutical innovation to transform cancer care worldwide.
At ITM, precision drives everything - from isotope manufacturing to cancer treatment—improving outcomes and delivering what patients and physicians expect.
transform cancercare worldwideitmradiopharmalead
https://orchestralifesciences.com/ols-brochure-2/
Radiopharma Brochure - Orchestra Life Sciences
life sciencesradiopharmabrochureorchestra
https://endpoints.news/regeneron-wades-into-radiopharma-through-40m-upfront-deal-with-telix/
Regeneron wades into radiopharma through $40M upfront deal with Telix
Regeneron is set to work on radiopharmaceuticals for the first time in a new partnership to develop solid tumour therapies as well as diagnostic agents with...
regeneronwadesradiopharma40mupfront
https://www.itm-radiopharma.com/home/
ITM Radiopharma: Lead radiopharmaceutical innovation to transform cancer care worldwide.
At ITM, precision drives everything - from isotope manufacturing to cancer treatment—improving outcomes and delivering what patients and physicians expect.
transform cancercare worldwideitmradiopharmalead
https://www.nature.com/articles/s43018-025-01044-8?error=cookies_not_supported&code=cb074d3b-1732-442b-8ac0-32cb0d15d90b
Radiopharma pipeline builds ahead of key data | Nature Cancer
Oct 6, 2025 - Investment continues as the field awaits phase 3 readouts for next-generation radioligand therapies in 2026.
builds aheadkey dataradiopharmapipelinenature